V.Kh. FAZYLOV, S.V. TKACHEVA, E.R. MANAPOVA

Kazan State Medical University, 49 Butlerov St., Kazan, Russian Federation, 420012 

Fazylov V.Kh. — D. Med. Sc., Professor, Head of The Department of Infectious Diseases, tel.: (843) 267-80-72, 8-917-254-89-97, e-mail: vildan47@rambler.ru

Tkacheva S.V. — Cand. Med. Sc., Associate Professor of the Department of Infectious Diseases, tel. (843) 267-80-99, e-mail: tkacheva-kgmu@mail.ru

Manapova E.R. — Cand. Med. Sc., Assistant Lecturer of the Department of Infectious Diseases, tel. (843) 267-80-99, e-mail: elveram@yandex.ru

Identification of single nucleotide polymorphisms (SNP) at rs8099917 and rs12979860 locuses of IL-28B gene was carried out in 58 patients with CHC. 30 of them had unfavorable genotypes СТ, ТТ (rs12979860) and ТG, GG (rs8099917) of IL-28 gene were divided into 3 groups depending on recurrent treatment scheme. The frequency of unfavorable genotypes СТ, ТТ of polymorphism rs12979860 and ТG, GG of polymorphism rs8099917 of IL-28 gene in CHC patients was 77.6% and 44.8% accordingly. Inclusion of cytokine drugs in the recurrent therapy (interferon-α and ribavirin) allowed to obtain a stable virusological response (SVR) in 44.4% of patients with an unfavorable IL28B genetic background, with biochemical response, lack of adverse effects requiring the cancellation of antiviral therapy or administration of intensive pathogenetic therapy. That allows to conclude that safety «Betaleukin ®» and «Ingaron» are safe in the schemes of antiviral therapy in combination with standard interferon-α and ribavirin in patients with recurrent HCV-infection.

Key words: chronic hepatitis C, antiviral therapy, cytokines, IL-28B genotypes.

REFERENCES

1. Zhdanov K.V., Kozlov K.V., Sukachev V.S. Evolution of antiviral therapy for chronic viral hepatitis B, C, D. Zhurnal infektologii, 2009, vol. 1, no. 4, pp. 23-35 (in Russ.).

2. Jacobson I.M., McHutchison J.G., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med., 2011, 364, no. 25, rr. 2405-2416.

3. Sherman K.E., Flamm S.L., Afdhal N.H. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med., 2011, vol. 365, no. 11. pp. 1014-1024.

4. Poordad F., Jr. McCone J., Bacon B.R. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med., 2011, vol. 364, no. 13, rr. 1195-1206.

5. Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology, 2010, 138, rr. 1338-1345.

6. McCarthy J., Li J., Thompson A. et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology, 2010, 138, rr. 2307-314.

7. Kozina A.N., Abramov D.D., Klimova E.A. et al. Opportunities personalized approach to the treatment of hepatitis C on the basis of the developed genetic tests determine the version of the gene polymorphism of IL-28B. Lechashchiy vrach, 2011, no. 10, pp. 39-43 (in Russ.).

8. Simbirtsev A.S. Interleykin-1. Fiziologiya. Patologiya. Klinika [Interleukin-1. Physiology. Pathology. Clinic]. Saint Petersburg: OOO “Izdatel’stvo Foliant”, 2011. 480 p.

9. Lobzin Yu.V., Zhdanov K.V., Simbirtsev A.S. et al. Efficacy and safety of triple therapy with recombinant interleukin-1ß, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, with the lack of response to previous treatment with interferon and ribavirin. Zhurnal infektologii, 2012, vol. 4, no. 4, pp. 81-89 (in Russ.).

10. Ershov F.I., Kiselev O.I. Interferony i ikh induktory (ot molekul do lekarstv) [Interferons and their inducers (from molecules to medicine)]. GOETAR-Media, 2005. 356 p.